



NAPPO

North American Plant Protection Organization

Organización Norteamericana de Protección a las Plantas

MEXICO - USA - CANADA

Seed Expert Group

Developing harmonized criteria for evaluating phytosanitary seed treatments



Christina Devorshak
USDA-APHIS-PPQ-Science and Technology
Chair of Expert Group
40th NAPPO Annual Meeting
November 1, 2016

2016-16 NAPPO Expert Group Members



Jean-François Dubuc, CFIA
Janine Maruschak, CFIA
Stephan Briere, CFIA
Karine Paré, CFIA
David Carey, Industry



Angela McMellen-
Brannigan, APHIS
Christina Devorshak,
APHIS
Dean Komm, APHIS
Ric Dunkle, Industry
Kelly Criss, Industry



Claudio Chavarin,
SENASICA
Noe Demetrio Sánchez
Isordia, SENASICA
Alejandra Elizalde,
Industry
Mario Puente, Industry

Project Title, Objectives and Deliverables

Objectives

- Develop a science and technology document providing a list of criteria for evaluating phytosanitary seed treatments;
- Identification of data gaps and research needs

Deliverables

- Development of a list of criteria for evaluating phytosanitary seed treatments
- Identification of data gaps and research needs where they may exist

Progress during 2016

- Six teleconferences
- A draft document has been developed
- Determine if stand-alone or appendix to seed standard
- Revision of draft for country consultation



Phytosanitary treatments for seeds questions

- IPPC standard on phytosanitary treatments (PTs) – ISPM 28
 - provides **general guidance** on how PTs are developed, types of information needed and other information on how a PT can be considered (for example, feasibility and impacts on the commodity)
 - **BUT** - guidance is more applicable to **arthropod pests**
 - Seeds are **NOT THE SAME** as other commodities (like fruit for consumption);
 - **AND** the types of pests most commonly associated with seeds are **PATHOGENS**

Phytosanitary treatments for seeds questions

- What constitutes an effective treatment;
- When should treatments be applied;
- How would countries agree that a treatment is (or is not) sufficient for managing risk;
- When (or if) verification through testing is justified;
- When (or if) additional testing after a treatment is appropriate;
- Whether seed is an epidemiologically significant pathway (what is the likelihood of pathogen introduction) after treatment; and,
- What impacts do the treatments have on the commodity?

Conclusions, next steps or proposed activities for 2017

- Finalize draft for country consultation
- Receive comments from country consultation and revise draft accordingly
- Provide to NAPPO Executive Committee for approval